Bluethmann Shirley M, Murphy Caitlin C, Tiro Jasmin A, Mollica Michelle A, Vernon Sally W, Bartholomew Leona Kay
Penn State University.
University of Texas Southwestern Medical Center.
Oncol Nurs Forum. 2017 May 1;44(3):E101-E110. doi: 10.1188/17.ONF.E101-E110.
PURPOSE/OBJECTIVES: Adjuvant endocrine therapy (AET) has been shown to improve survival in hormone receptor-positive breast cancer survivors, but as many as half do not complete recommended treatment. Management of medication-related side effects and engagement with providers are two potentially modifiable factors, but their associations with adherence are not well understood. The aims were to build on survey results to qualitatively explore survivors' experiences with prescribed AET to (a) describe appraisal and management of AET side effects and (b) deconstruct decisions to initiate, discontinue, or maintain AET. .
RESEARCH APPROACH: The authors used a mixed-methods explanatory sequence research design with a qualitative emphasis. .
SETTING: Survivors were recruited from a clinical cancer registry maintained at the University of Texas Southwestern Medical Center, which includes the Harold C. Simmons Comprehensive Cancer Center (National Cancer Institute-designated), in Dallas. .
PARTICIPANTS: 452 survivors completed a survey, and 30 took part in telephone interviews. .
METHODOLOGIC APPROACH: Qualitative methods were used in which the authors recorded and transcribed interviews for analysis and used open coding to reduce data into themes. .
FINDINGS: Among adherent survivors, the themes of tolerance of side effects and perseverance were strong. Nonadherent survivors expressed more difficulty managing side effects and perceived fewer benefits when side effects were bothersome. The most common side effects mentioned by all survivors were menopausal symptoms and joint pain; less common side effects were cognitive decline and cardiac distress. Some sought advice from their oncology team. Nonadherent survivors appeared initially motivated to maintain AET but identified a tolerance limit for side effects after which a provider's recommendation was less influential in their decision to maintain or discontinue AET. .
INTERPRETATION: This study elucidated adherence as a complex continuum of behaviors, appraisals, and decision points. These insights may be particularly useful in counseling survivors taking AET and promoting timely delivery of clinical interventions to enhance adherence. .
Nurses should be involved in the planning and implementation of clinical interventions to manage side effects and other barriers to AET adherence.
目的/目标:辅助内分泌治疗(AET)已被证明可提高激素受体阳性乳腺癌幸存者的生存率,但多达一半的患者未完成推荐治疗。药物相关副作用的管理以及与医疗服务提供者的沟通是两个可能可改变的因素,但它们与依从性的关联尚未得到充分理解。本研究旨在基于调查结果,定性地探索幸存者接受规定的AET的经历,以(a)描述AET副作用的评估和管理,以及(b)剖析开始、停止或维持AET的决定因素。
作者采用了以定性为主的混合方法解释性序列研究设计。
幸存者从德克萨斯大学西南医学中心维护的临床癌症登记处招募,该中心包括位于达拉斯的哈罗德·C·西蒙斯综合癌症中心(国家癌症研究所指定)。
452名幸存者完成了一项调查,30人参与了电话访谈。
采用定性方法,作者记录并转录访谈内容进行分析,并使用开放编码将数据归纳为主题。
在坚持治疗的幸存者中,副作用耐受性和毅力的主题较为突出。不坚持治疗的幸存者表示在管理副作用方面困难更大,并且当副作用令人困扰时,他们认为获益更少。所有幸存者提到的最常见副作用是更年期症状和关节疼痛;较不常见的副作用是认知能力下降和心脏不适。一些人向肿瘤学团队寻求建议。不坚持治疗的幸存者最初似乎有动力维持AET,但确定了副作用的耐受极限,在此之后,医疗服务提供者的建议对他们维持或停止AET的决定影响较小。
本研究阐明了依从性是一个包括行为、评估和决策点的复杂连续体。这些见解可能对为接受AET的幸存者提供咨询以及促进及时提供临床干预措施以提高依从性特别有用。
护士应参与临床干预措施的规划和实施,以管理副作用及其他影响AET依从性的障碍。